[High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
32 patients suffering from previously untreated, advanced metastatic or non-metastatic prostatic carcinoma, were studied in an assessment of the effect of high-dose medroxyprogesterone acetate (MPA) on the hormonal parameters testosterone and the luteinizing hormone (LH). The dose used was 500 mg intramuscularly daily for a week, followed by 1000 mg monthly until progression or for a minimal period of 12 months. Full castration was achieved and this effect was maintained during the observation period. Stable disease was seen in 20 patients (63%) whilst progression of disease was found in 12 patients (37%). 4 patients were non-responders. The incidence of side effects was 31%.
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D000970:Antineoplastic Agents; D013739:Testosterone; D007986:Luteinizing Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Hochdosierte Medroxy-Progesteron-Acetat-(MPA-)Behandlung beim fortgeschrittenen Prostatakarzinom.